Trelstar is a drug owned by Verity Pharmaceuticals Inc. It is protected by 2 US drug patents filed from 2013 to 2019. Out of these, 1 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 30, 2029. Details of Trelstar's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5776885 | Sustained and controlled release of water insoluble polypeptides |
Jul, 2015
(9 years ago) |
Expired
|
| US10166181 | Slow release pharmaceutical composition made of microgranules |
Jun, 2029
(4 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Trelstar's patents.
Latest Legal Activities on Trelstar's Patents
Given below is the list of recent legal activities going on the following patents of Trelstar.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Jul, 2022 | US10166181 |
| Post Issue Communication - Certificate of Correction | 08 Jan, 2020 | US10166181 |
| Email Notification | 27 Sep, 2019 | US10166181 |
| Mail-Petition Decision - Dismissed | 24 Sep, 2019 | US10166181 |
| Petition Decision - Dismissed | 23 Sep, 2019 | US10166181 |
| Email Notification | 06 Mar, 2019 | US10166181 |
| Change in Power of Attorney (May Include Associate POA) | 06 Mar, 2019 | US10166181 |
| Petition Entered | 25 Feb, 2019 | US10166181 |
| Patent Issue Date Used in PTA Calculation | 01 Jan, 2019 | US10166181 |
| Recordation of Patent Grant Mailed | 01 Jan, 2019 | US10166181 |
Several oppositions have been filed on Trelstar's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Trelstar's generic, the next section provides detailed information on ongoing and past EP oppositions related to Trelstar patents.
Trelstar's oppositions filed in EPO
Trelstar has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 13, 2017, by Generics (Uk) Ltd. This opposition was filed on patent number EP08763237A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP12172232A | Apr, 2019 | Generics [UK] Ltd | Granted and Under Opposition |
| EP08763237A | Sep, 2017 | Ferring B.V. | Revoked |
| EP08763237A | Sep, 2017 | Generics (UK) Ltd | Revoked |
US patents provide insights into the exclusivity only within the United States, but Trelstar is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Trelstar's family patents as well as insights into ongoing legal events on those patents.
Trelstar's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Trelstar's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 30, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Trelstar Generics:
There are no approved generic versions for Trelstar as of now.
About Trelstar
Trelstar is a drug owned by Verity Pharmaceuticals Inc. Trelstar uses Triptorelin Pamoate as an active ingredient. Trelstar was launched by Verity in 2001.
Market Authorisation Date:
Trelstar was approved by FDA for market use on 29 June, 2001.
Active Ingredient:
Trelstar uses Triptorelin Pamoate as the active ingredient. Check out other Drugs and Companies using Triptorelin Pamoate ingredient
Dosage:
Trelstar is available in injectable form for intramuscular use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 11.25MG BASE/VIAL | INJECTABLE | Prescription | INTRAMUSCULAR |
| EQ 22.5MG BASE/VIAL | INJECTABLE | Prescription | INTRAMUSCULAR |
| EQ 3.75MG BASE/VIAL | INJECTABLE | Prescription | INTRAMUSCULAR |